The impact of wearing ‘OFF’ (WO) episodes on non-motor symptoms (NMS) burden and quality of life (QoL) in Parkinson’s disease (PD) patients
Objective: To estimate the frequency and severity of NMS and their impact on QoL among patients with moderate to advanced PD with WO episodes versus…Development and Clinimetric Testing Plan for the MDS Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS)
Objective: Present the development process and clinimetric testing plan for the International Parkinson and Movement Disorder Society Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS). Background: Psychosis…Longitudinal assessment of evolution and plasma biomarkers for depression and anxiety in Parkinson’s disease
Objective: We aimed to investigatethe evolution of depression and anxietyin a large Parkinson's disease (PD) cohort and explore the related plasma biomarkers. Background: Depression and anxietyare common non-motor…Role of ATP10B variants in Parkinson Disease in a southern Spanish cohort
Objective: The objective of our study was to evaluate the role of ATP10B variants in Parkinson disease (PD) in a southern Spanish cohort of PD…Cerebrospinal fluid biomarkers for diagnosis of Parkinson’s disease: a systematic review and network meta-analysis
Objective: In this study, we intended to use network meta-analysis to compare the diagnostic performances of different CSF biomarkers in the diagnosis and differential diagnosis…Salivary α-synuclein in Parkinson’s disease – a pilot study
Objective: The aim of our study was to measure total salivary α-synuclein in Parkinson´s disease (PD) patients to assess its potential as a biomarker of…Physical exercise as a promising option for treating fatigue in Parkinson’s disease? Results of a systematic review and meta-analysis of non-pharmacological interventions
Objective: To give an update on randomized controlled trials (RCT) including non-pharmacological intervention approaches that examine effects on fatigue in people with Parkinson’s disease (PD).…Using mediation analysis to account for the effect of Parkinson’s Disease medications on disease progression
Objective: To explore the use of mediation analysis to incorporate L-dopa equivalent daily dose (LEDD) for disease progression of Parkinson’s Disease (PD) in a simulation…Open-label Extension Study of Long-term Safety and Tolerability of Foslevodopa/Foscarbidopa for Treatment of Advanced Parkinson’s Disease
Objective: To evaluate long-term safety/tolerability of foslevodopa/foscarbidopa (LDP/CDP) in patients with advanced Parkinson’s disease (aPD) in a phase 3 open-label extension (OLE) study. Background: LDP/CDP…A non-expensive bidimensional assessment can detect subtle alterations in gait performance in people in the early stages of Parkinson’s disease
Objective: To investigate the effectiveness of a two-dimensional gait assessment to identify the decline in gait performance associated with Parkinson's disease progression Background: Gait is…
- « Previous Page
- 1
- …
- 151
- 152
- 153
- 154
- 155
- …
- 338
- Next Page »